Two‐year persistence of golimumab as second‐line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real‐life data from the LORHEN registry期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Two‐year persistence of golimumab as second‐line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real‐life data from the LORHEN registry

Authors:	Ennio G. Favalli Luigi Sinigaglia Andrea Becciolini Vittorio Grosso Roberto Gorla Chiara Bazzani Fabiola Atzeni Pier C. Sarzi Puttini Enrico Fusaro Raffaele Pellerito Roberto Caporali

Affiliation:	1. Department of Rheumatology, Gaetano Pini Institute, Milan, Italy;2. Department of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy;3. Rheumatology and Immunology Unit, University of Brescia, Spedali Civili, Brescia, Italy;4. Rheumatology Unit, University of Milan, L. Sacco Hospital, Milan, Italy;5. Department of Rheumatology, Azienda Ospedaliero‐Universitaria Città della Salute e della Scienza, Torino, Italy;6. Rheumatology Unit, Ospedale Mauriziano, Torino, Italy

Abstract:

Keywords:	anti‐TNF biologic agents drug survival golimumab rheumatoid arthritis second line treatment